Tier 2 — strong

Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine: A double-blind randomized clinical trial

Zohreh Sajadi Hezaveh, Azita Azarkeivan, Leila Janani, Farzad Shidfar
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2019 24:91

Bibliography

PubMed
PMID 31741663
PubMed Central
PMC6856539
DOI
10.4103/jrms.JRMS_911_18
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: There are no conflicts of interest.

Study snapshot

DesignRandomized double-blind placebo-controlled adjunctive trial
ModelHuman intervention research
Sample84 adults with beta-thalassemia receiving desferrioxamine
InterventionQuercetin 500 mg/day versus placebo
Duration12 weeks
EndpointsOxidative-stress measures; Liver measurements; Protein activity, binding or signaling

What the study showed, in plain terms

Published in 2019, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled adjunctive trial. Sample/model: 84 adults with beta-thalassemia receiving desferrioxamine. The exposure or intervention was Quercetin 500 mg/day versus placebo. Follow-up or treatment period: 12 weeks.

ALT decreased compared with placebo. Most antioxidant and liver-enzyme endpoints did not differ significantly.

Adjunctive rare-disease trial with multiple endpoints. A single enzyme change does not establish general liver protection.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • ALT decreased compared with placebo.
  • Most antioxidant and liver-enzyme endpoints did not differ significantly.
  • The recorded outcome domains were Oxidative-stress measures; Liver measurements; Protein activity, binding or signaling.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus placebo; 12 weeks.

What this study can and cannot tell us

  • Adjunctive rare-disease trial with multiple endpoints. A single enzyme change does not establish general liver protection.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology